Finoriq research workspace

ASSEMBLY BIOSCIENCES, INC. (ASMB) Company Overview

Assembly Biosciences, Inc., a biotechnology company, develops therapeutic candidates for the treatment of. Review ASMB filings, fundamentals, valuation, and ownership on Finoriq.

Company Snapshot

Assembly Biosciences, Inc., a biotechnology company, develops therapeutic candidates for the treatment of viral diseases worldwide. Its pipeline includes long-acting helicase-primase inhibitors candidates, including ABI-5366 and ABI-1179, which are in Phase 1 clinical studies for recurrent genital herpes; and ABI-6250, an orally bioavailable hepatitis delta virus entry inhibitor that is in Phase 1a clinical study for the treatment of chronic hepatitis delta virus (HDV) infection. The company also develops ABI-4334, an orally bioavailable next generation capsid assembly modulator that is in Phase 1b study clinical trial for the treatment of chronic hepatitis B virus (HBV) infection; and ABI-7272, an oral broad-spectrum NNPI for the treatment of transplant-associated herpesviruses. It has an option, license, and collaboration agreement with Gilead Sciences, Inc. for the research and development of virology therapies. The company was formerly known as Ventrus Biosciences, Inc. and changed its name to Assembly Biosciences, Inc. in June 2014. Assembly Biosciences, Inc. was incorporated in 2005 and is headquartered in South San Francisco, California.

Company

ASSEMBLY BIOSCIENCES, INC. (ASMB)

Ticker

ASMB

Market Cap

$402.7M

Latest Price

$25.34

Industry

Biotech & Pharma

Open insider transactions

ASSEMBLY BIOSCIENCES, INC. (ASMB) Current Valuation Metrics

Static valuation preview for ASSEMBLY BIOSCIENCES, INC. (ASMB). Market data retrieved 2026-07-09. Filing currency USD.

Live data loads in the app

This static page shell gives search engines reliable page context. Current tables, filings, charts, and market data continue to load from Finoriq APIs after the application starts.